MétaCan
Menu
Back to cohort

Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial

2022· article· en· W4293332312 on OpenAlexaboutno aff
Jawad H. Butt, Pardeep S. Jhund, Jan Bělohlávek, Rudolf A. de Boer, Chern‐En Chiang, Akshay S. Desai, Jarosław Dróżdż, Adrian F. Hernandez, Silvio E. Inzucchi, Tzvetana Katova, Masafumi Kitakaze, Mikhail Kosiborod, Carolyn S.P. Lam, Anna Maria Langkilde, Daniel Lindholm, Erasmus Bachus, Felipe A. Martínez, Béla Merkely, Magnus Petersson, Jose F. Kerr Saraiva, Sanjiv J. Shah, Muthiah Vaduganathan, Orly Vardeny, Ulrica Wilderäng, Brian Claggett, Scott D. Solomon, John J.V. McMurray

Bibliographic record

VenueCirculation · 2022
Typearticle
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsnot available
FundersRelypsaNational Medical Research CouncilRespicardiaAmerican RegentNational Heart, Lung, and Blood InstituteJapan Heart FoundationVifor PharmaDaiichi-SankyoUniversity of GlasgowPfizerModernaMedical Research CouncilVerily Life SciencesBritish Heart FoundationCytokineticsIonis PharmaceuticalsNational Institutes of HealthRegeneron PharmaceuticalsSarepta TherapeuticsJapan Agency for Medical Research and DevelopmentSanofi PasteurUniversitair Medisch Centrum GroningenKowa CompanyCelladon CorporationDefense Acquisition Program AdministrationBoston Scientific CorporationEsperion TherapeuticsAlnylam PharmaceuticalsNovo NordiskMyoKardiaDaiichi Sankyo EuropeServierBayerGilead SciencesNational Institute of Diabetes and Digestive and Kidney DiseasesSanofiGlaxoSmithKlineAmgenAstraZenecaLundbeckfondenEli Lilly and CompanyBristol-Myers Squibb
KeywordsMedicineDapagliflozinHeart failureEjection fractionHazard ratioClinical endpointInternal medicineTolerabilityRandomized controlled trialCanadian Cardiovascular SocietyCardiologyConfidence intervalAdverse effectMyocardial infarctionDiabetes mellitusAnginaType 2 diabetes

Abstract

fetched live from OpenAlex

Background: Frailty is increasing in prevalence. Because patients with frailty are often perceived to have a less favorable risk/benefit profile, they may be less likely to receive new pharmacologic treatments. We investigated the efficacy and tolerability of dapagliflozin according to frailty status in patients with heart failure with mildly reduced or preserved ejection fraction randomized in DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure). Methods: Frailty was measured using the Rockwood cumulative deficit approach. The primary end point was time to a first worsening heart failure event or cardiovascular death. Results: Of the 6263 patients randomized, a frailty index (FI) was calculable in 6258. In total, 2354 (37.6%) patients had class 1 frailty (FI ≤0.210; ie, not frail), 2413 (38.6%) had class 2 frailty (FI 0.211–0.310; ie, more frail), and 1491 (23.8%) had class 3 frailty (FI ≥0.311; ie, most frail). Greater frailty was associated with a higher rate of the primary end point (per 100 person-years): FI class 1, 6.3 (95% CI 5.7–7.1); class 2, 8.3 (7.5–9.1); and class 3, 13.4 (12.1–14.7; P <0.001). The effect of dapagliflozin (as a hazard ratio) on the primary end point from FI class 1 to 3 was 0.85 (95% CI, 0.68–1.06), 0.89 (0.74–1.08), and 0.74 (0.61–0.91), respectively ( P interaction =0.40). Although patients with a greater degree of frailty had worse Kansas City Cardiomyopathy Questionnaire scores at baseline, their improvement with dapagliflozin was greater than it was in patients with less frailty: placebo-corrected improvement in Kansas City Cardiomyopathy Questionnaire Overall Summary Score at 4 months in FI class 1 was 0.3 (95% CI, −0.9 to 1.4); in class 2, 1.5 (0.3–2.7); and in class 3, 3.4 (1.7–5.1; P interaction =0.021). Adverse reactions and treatment discontinuation, although more frequent in patients with a greater degree of frailty, were not more common with dapagliflozin than with placebo irrespective of frailty class. Conclusions: In DELIVER, frailty was common and associated with worse outcomes. The benefit of dapagliflozin was consistent across the range of frailty studied. The improvement in health-related quality of life with dapagliflozin occurred early and was greater in patients with a higher level of frailty. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03619213.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.013
Threshold uncertainty score0.143

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.019
GPT teacher head0.249
Teacher spread0.230 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations150
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueCirculationSame topicDiabetes Treatment and ManagementFrench-language works237,207